Andrew Saxon, MD
Personal Statement
My area of expertise is addiction psychiatry.
Department Affiliations
Centers/Programs
Training Programs
Scholarly Expertise
Teaching Philosophy
My training philosophy involves serving as a role model for my trainees as well as generally apply a supportive, Socratic method.
- NIDA Clinical Trials Network: Pacific Northwest Node
- Improving the implementation of smartphone-based contingency management in medical settings for the treatment of methamphetamine use disorder: a qualitative analysis of patient and clinician experiences
- Improving opioid use disorder treatment using contingency management via mHealth
- Impact of medical and recreational marijuana laws on cannabis, opioids and psychiatric medications: national study of VA patients, 2000 – 2024
- Preventing addiction related suicide
- Evaluating the Stepped Care for Opioid Use Disorder Train-the-Trainer (SCOUTT) Program
- Collaborating to Heal Addiction and Mental Health in Primary Care (CHAMP)
Recent Publications
Cannabis legalization and cannabis use disorder in United States Veterans Health Administration patients with and without psychiatric disorders, 2005-2022: a repeated cross-sectional study.
(2025 Aug)
Lancet Reg Health Am 48(): 101155
Hasin DS, Malte C, Wall MM, Alschuler D, Simpson TL, Olfson M, Livne O, Mannes ZL, Fink DS, Keyes KM, Cerdá M, Maynard CC, Keyhani S, Martins SS, Sherman S, Saxon AJ
(2025 Aug)
Lancet Reg Health Am 48(): 101155
Hasin DS, Malte C, Wall MM, Alschuler D, Simpson TL, Olfson M, Livne O, Mannes ZL, Fink DS, Keyes KM, Cerdá M, Maynard CC, Keyhani S, Martins SS, Sherman S, Saxon AJ
Promising Opportunities to Intervene on Adolescent Substance Use.
(2025 Jul 1)
Am J Psychiatry 182(7): 596-598
Saxon AJ, Olfson M, Hsiao R, Hasin DS
(2025 Jul 1)
Am J Psychiatry 182(7): 596-598
Saxon AJ, Olfson M, Hsiao R, Hasin DS
Cannabis Legalization and Opioid Use Disorder in Veterans Health Administration Patients.
(2025 Jun 7)
JAMA Health Forum 6(6): e251369
Mannes ZL, Wall MM, Alschuler DM, Malte CA, Olfson M, Livne O, Fink DS, Keyhani S, Keyes KM, Martins SS, Cerdá M, Sacco DL, Gutkind S, Maynard CC, Sherman S, Saxon AJ, Hasin DS
(2025 Jun 7)
JAMA Health Forum 6(6): e251369
Mannes ZL, Wall MM, Alschuler DM, Malte CA, Olfson M, Livne O, Fink DS, Keyhani S, Keyes KM, Martins SS, Cerdá M, Sacco DL, Gutkind S, Maynard CC, Sherman S, Saxon AJ, Hasin DS
Challenging the Utility of DSM-5 Opioid Use Disorder Criteria for Diagnosing Problematic Prescription Opioid Use: Next Steps.
(2025 Jun 6)
J Addict Med
Ballantyne JC, Sullivan MD, Saxon AJ
(2025 Jun 6)
J Addict Med
Ballantyne JC, Sullivan MD, Saxon AJ
Implementing buprenorphine for opioid use disorder in veterans health administration primary care: a qualitative analysis.
(2025 Apr 30)
Addict Sci Clin Pract 20(1): 38
Lott A, Danner AN, Malte CA, Salameh HA, Bachowski D, Gordon AJ, Hagedorn HJ, Frost MC, Williams EC, Saxon AJ, Trim RS, Hawkins EJ
(2025 Apr 30)
Addict Sci Clin Pract 20(1): 38
Lott A, Danner AN, Malte CA, Salameh HA, Bachowski D, Gordon AJ, Hagedorn HJ, Frost MC, Williams EC, Saxon AJ, Trim RS, Hawkins EJ
Show complete publication list »
